These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 17893871)

  • 21. Expression profiles of pancreatic cancer cell lines infected with antisense K-ras-expressing adenoviral vector.
    Ohnami S; Aoki K; Yoshida K; Ohnami S; Hatanaka K; Suzuki K; Sasaki H; Yoshida T
    Biochem Biophys Res Commun; 2003 Oct; 309(4):798-803. PubMed ID: 13679043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells.
    Agbunag C; Bar-Sagi D
    Cancer Res; 2004 Aug; 64(16):5659-63. PubMed ID: 15313904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions.
    Funel N; Morelli M; Giovannetti E; Del Chiaro M; Pollina LE; Mosca F; Boggi U; Cavazzana A; Campani D
    Pancreatology; 2011; 11(1):30-42. PubMed ID: 21412023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
    Singh P; Wig JD; Srinivasan R; Radotra BD
    Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.
    Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH
    Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification.
    Seki K; Suda T; Aoyagi Y; Sugawara S; Natsui M; Motoyama H; Shirai Y; Sekine T; Kawai H; Mita Y; Waguri N; Kuroiwa T; Igarashi M; Asakura H
    Clin Cancer Res; 2001 Jul; 7(7):1976-81. PubMed ID: 11448913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes.
    Kita K; Saito S; Morioka CY; Watanabe A
    Int J Cancer; 1999 Feb; 80(4):553-8. PubMed ID: 9935156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of K-ras codon 12 and 13 mutations found in pancreatic adenocarcinoma of 30 Chinese patients by microdissection, PCR and direct sequencing.
    Wei S; Liang Z; Gao J; Wu S; Zhu H; Liu H; Liu T
    J Gastroenterol Hepatol; 2005 Jan; 20(1):67-72. PubMed ID: 15610449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.
    Sato N; Matsubayashi H; Abe T; Fukushima N; Goggins M
    Clin Cancer Res; 2005 Jul; 11(13):4681-8. PubMed ID: 16000561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells.
    Tsuchida T; Kijima H; Oshika Y; Tokunaga T; Abe Y; Yamazaki H; Tamaoki N; Ueyama Y; Scanlon KJ; Nakamura M
    Biochem Biophys Res Commun; 1998 Dec; 253(2):368-73. PubMed ID: 9878544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
    Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
    Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas.
    Kitago M; Ueda M; Aiura K; Suzuki K; Hoshimoto S; Takahashi S; Mukai M; Kitajima M
    Int J Cancer; 2004 Jun; 110(2):177-82. PubMed ID: 15069678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.
    Dergham ST; Dugan MC; Arlauskas P; Du W; Vaitkevicius VK; Crissman JD; Sarkar FH
    Int J Pancreatol; 1997 Jun; 21(3):225-34. PubMed ID: 9322121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
    Lüttges J; Schlehe B; Menke MA; Vogel I; Henne-Bruns D; Klöppel G
    Cancer; 1999 Apr; 85(8):1703-10. PubMed ID: 10223563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.
    Erill N; Cuatrecasas M; Sancho FJ; Farré A; Pour PM; Lluís F; Capellá G
    Am J Pathol; 1996 Oct; 149(4):1333-9. PubMed ID: 8863680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma.
    DiGiuseppe JA; Hruban RH; Offerhaus GJ; Clement MJ; van den Berg FM; Cameron JL; van Mansfeld AD
    Am J Pathol; 1994 May; 144(5):889-95. PubMed ID: 8178941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status.
    Lüttges J; Neumann S; Jesenofsky R; Borries V; Löhr M; Klöppel G
    Pancreas; 2003 Oct; 27(3):e57-62. PubMed ID: 14508142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combinational effects of K-ras and IGF-IR antisense oligodeoxynucleotide on proliferation and apoptosis of human pancreatic cancer Patu8988 cells].
    Shen YM; Yang XC; Zhang MH; Shen JK; Sun YH
    Ai Zheng; 2008 May; 27(5):496-504. PubMed ID: 18479599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.
    Pellegata NS; Sessa F; Renault B; Bonato M; Leone BE; Solcia E; Ranzani GN
    Cancer Res; 1994 Mar; 54(6):1556-60. PubMed ID: 8137263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma.
    Ikeda N; Nakajima Y; Sho M; Adachi M; Huang CL; Iki K; Kanehiro H; Hisanaga M; Nakano H; Miyake M
    Cancer; 2001 Aug; 92(3):488-99. PubMed ID: 11505392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.